ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 8, 2015

9:00AM-11:00AM
Abstract Number: 272
Are the Autoimmune/Inflammatory Syndrome Induced By Adjuvants (ASIA) and the Undifferentiated Connective Tissue Disease (UCTD) Related to Each Other? a Case-Control Study of Environmental Exposures
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
9:00AM-11:00AM
Abstract Number: 801
Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 661
ASDAS Can be Reliably Calculated When Only the Patient’s Overall Basdai Score Is Available, but Not the Score(S) of Its Individual Component(S)
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments
9:00AM-11:00AM
Abstract Number: 650
ASDAS-Based Remission Was Less Frequent Than Basdai-Based Remission, and Both Were Related to CRP and Smoking in Early Axial Spondyloarthritis
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments
9:00AM-11:00AM
Abstract Number: 638
Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach
Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 669
Assessment of Spinal Mobility in Axial Spondyloarthritis: First Validation Steps of a New Electronic Quantification Tool
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments
9:00AM-11:00AM
Abstract Number: 356
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster
9:00AM-11:00AM
Abstract Number: 642
Assignable Causes for Fatigue in Primary Sjögren’s Syndrome: Data from the UK Primary Sjögren’s Syndrome Registry
Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 726
Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I
9:00AM-11:00AM
Abstract Number: 354
Association Between Bone and Clinical Parameters in Ankylosing Spondylitis
Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster
9:00AM-11:00AM
Abstract Number: 525
Association Between Fine Specificity of Anti-Citrullinated Peptide Antibodies and High Resolution Computed Tomography Parenchymal Lung Changes in Patients with Early RA
Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 692
Association Between Improvement in Enthesopathy and Quality of Life: Results from a Phase 3 T in Psoriatic Arthritis Patients
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments
9:00AM-11:00AM
Abstract Number: 639
Association Between Insomnia and EULAR Sjögren’s Syndrome Patient-Reported Index in Korean Patients with Primary Sjögren’s Syndrome
Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 573
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I
9:00AM-11:00AM
Abstract Number: 267
Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
  • «Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 73
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology